[Alpha Tau in Alpha Tau] Alpha Tau successfully treats first patient in its U.S. trial for patients with recurrent glioblastoma at the James Cancer Hospital at The Ohio State University

Jerusalem, December 9, 2025 – Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT^® today announced that the first patient has been treated in its pilot study for the treatment of patients with recurrent glioblastoma multiforme (GBM) using the Alpha DaRT technology.

Read more here.